InnovAntiBiofilm
Boosting Sustainable Innovation in Developing New Antibiotic Adjuvants to Control Biofilm Resistance
InnovAntiBiofilm, funded by the Horizon Europe, will address the challenges defined in the European Partnership One Health Action Plan against Antimicrobial Resistance (AMR) and contribute to the objectives of the Pharmaceutical Strategy for Europe
THE PROBLEM
THE BACTERIAL RESISTANCE CHALLENGE
About 1.3 million people worldwide die of resistant bacterial infections each year.
Antibiotic resistant infections could be responsible for an additional 10 million deaths each year by 2050.
No new antibiotics have been approved since 2019.
IMPACT OF BIOFILMS
Over 80% of bacterial infections in humans involve the formation of biofilm.
Bacteria in biofilms can be 10 to 1000 times more resistant to antibiotics than their planktonic counterparts.
Biofilm-associated infections are related to increased patient morbidity and mortality rates, constituting a significant economic burden.
OUR SOLUTIONS
InnovAntiBiofilm will address the challenges defined in the European Partnership One Health Action Plan against Antimicrobial Resistance (AMR) and contribute to the objectives of the Pharmaceutical Strategy for Europe.
Sustainable Development of Antibiotic Adjuvants
Development of Innovative Phytochemical Derivatives
Capacity Building and Networking
Strengthening R&D Competitiveness and Administrative Skills
CONTACT US
Address
LEPABE – Department of Chemical Engineering, Faculty of Engineering, University of Porto
Rua Dr. Roberto Frias, s/n 4200-465 Porto, Portugal
Follow us
Get the latest news and updates
Funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them. Grant agreement No. 101157363.